These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 36161293)
1. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy. Zhang Q; Zu C; Meng Y; Lyu Y; Hu Y; Huang H Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):144-150. PubMed ID: 36161293 [TBL] [Abstract][Full Text] [Related]
2. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma. Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H Front Immunol; 2023; 14():1125357. PubMed ID: 37215107 [TBL] [Abstract][Full Text] [Related]
3. Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma. Lyu Y; Zhang M; Wei G; Ding S; Hu Y; Huang H Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):137-143. PubMed ID: 36161296 [TBL] [Abstract][Full Text] [Related]
4. Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma. Zu C; Wang K; Zhang Q; Hu Y; Huang H Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):160-166. PubMed ID: 36161295 [TBL] [Abstract][Full Text] [Related]
5. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Banerjee R; Marsal J; Huang CY; Lo M; Thiruvengadam SK; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353 [TBL] [Abstract][Full Text] [Related]
6. [Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2]. Xu XZ; Liu R; Zhao WH; Yang Y; Liu J; Zhang WG; Bai J; He AL Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):838-844. PubMed ID: 38049336 [No Abstract] [Full Text] [Related]
7. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210 [TBL] [Abstract][Full Text] [Related]
8. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J Front Immunol; 2021; 12():755866. PubMed ID: 34777368 [TBL] [Abstract][Full Text] [Related]
9. Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma. Josyula S; Pont MJ; Dasgupta S; Song X; Thomas S; Pepper G; Keane-Candib J; Stevens-Ayers TL; Ochs HD; Boeckh MJ; Riddell SR; Cowan AJ; Krantz EM; Green DJ; Hill JA Transplant Cell Ther; 2022 Jun; 28(6):304.e1-304.e9. PubMed ID: 35288345 [TBL] [Abstract][Full Text] [Related]
10. [Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA]. Sun Q; Qi YK; Qi KM; Yan ZL; Cheng H; Chen W; Zhu F; Sang W; Li DP; Cao J; Shi M; Li ZY; Xu KL Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):832-837. PubMed ID: 38049335 [No Abstract] [Full Text] [Related]
11. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma]. Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362 [No Abstract] [Full Text] [Related]
12. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. Reyes KR; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Olin RL; Martin T; Shah N; Banerjee R Transplant Cell Ther; 2023 Jun; 29(6):350-355. PubMed ID: 36933659 [TBL] [Abstract][Full Text] [Related]
13. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717 [TBL] [Abstract][Full Text] [Related]
14. Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature. Zhao G; Wei R; Feng L; Wu Y; He F; Xiao M; Cheng Z Cancer Immunol Immunother; 2022 Jan; 71(1):39-44. PubMed ID: 34003300 [TBL] [Abstract][Full Text] [Related]
15. BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S; Chandrakasan S; Leung K; Bryson E; Deeb L; Kaufman JL; Worthington-White D; Alazraki A; Schecter JM; Madduri D; Jackson CC; Zudaire E; Taraseviciute-Morris A; Babich A; Nesheiwat T; Vogel M; Lendvai N; Pacaud L; Williams KM J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37137553 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681 [TBL] [Abstract][Full Text] [Related]
17. Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy. Zhang M; Zhou L; Zhao H; Zhang Y; Wei G; Hong R; Wu W; Xu H; Wang L; Ni F; Cui J; Peng S; Huang CH; Chang AH; Hu Y; Huang H Clin Cancer Res; 2021 Dec; 27(23):6384-6392. PubMed ID: 34548316 [TBL] [Abstract][Full Text] [Related]
18. Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma. Wang X; Zhao L; Wang J; Yao Y; Wang J; Ji S; Hua T; Wang S; Cheng H; Shi M; Li Z; Zeng L; Zheng J; Xu K; Cao J Front Immunol; 2022; 13():814548. PubMed ID: 35572513 [TBL] [Abstract][Full Text] [Related]
19. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy]. Cui R; Li P; Li Q; Mu J; Jiang YL; Jiang YY; Deng Q Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):502-507. PubMed ID: 34384157 [No Abstract] [Full Text] [Related]
20. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma]. Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066 [No Abstract] [Full Text] [Related] [Next] [New Search]